gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CRBUHealthcareBiotechnology

Caribou Biosciences, Inc. Common Stock (CRBU)

$0.4069−8.44%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.41▼ 81.42% in range
Nov 5, 2025Low $0.41 · High $2.43Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Caribou Biosciences closed at $0.41 on Nov 5, down 8.44%, within 0.0% of its 52-week closing low. Volume of 1.1M shares was 0.29× its 20-day average (below normal).

Split-adjusted performance: -34.1% over one month, -78.4% over six months, -81.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.50M, down 43.8% from a year earlier, with a net margin of -1619.9%.

Short interest was 12.6M shares at the Oct 15 settlement, down 2.8% from the prior report (13.5% of float, 1.5 days to cover).

Market cap$43.6M107.2M shares
Revenue · quarter$1.5M−43.8% YoY
Diluted EPS$-0.24—
P/E · TTM—P/S 4.3×
Net margin-1,619.9%Gross 100.0%
Dividend yieldNone
52-week range0.41 – 2.43−83.3% from high
Volume1.1M0.29× 20-day avg
Volatility · 60d146.7%Annualised
Short % of float13.5%1.5 days to cover
Net cash$112.3MCash $112.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −8.6%1M −34.1%3M −75.3%6M −78.4%YTD −74.4%1Y −81.2%3Y −88.8%5Y −98.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum7
Revenue growth28
Net margin23
Value (low P/E)—
Size24

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →
Shares short12.6M−2.8% vs prior
Days to cover1.5Settled Oct 15
% of float13.5%
Short vol. 10d57.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CRBUCaribou Biosciences$0.4069−8.44%−78.4%−43.8%−1619.9%—$43.6M
IMAImageneBio$4.08−0.49%−31.0%———$46.3MCompare
LONALeonaBio$4.32−5.40%−56.2%———$40.7MCompare
TILInstil Bio$6.97−0.29%−13.2%———$47.3MCompare
GRMLGreenland Mines$3.62−7.42%————$49.5MCompare
EXOZeXoZymes$4.11−4.64%−58.9%———$38.2MCompare
KLRSKalaris Therapeutics$2.10+3.96%−59.2%———$50.0MCompare
PTHSPelthos Therapeutics$9.55−5.91%−61.8%—−150.1%—$37.5MCompare
ELOXEloxx Pharmaceuticals$12.59−1.18%————$50.8MCompare

News about Caribou Biosciences

All news →
Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research · 1d ago▲ PositiveCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswire Inc. · Jun 29, 2026▲ PositiveCaribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual MeetingGlobeNewswire Inc. · Jun 11, 2026▲ Positive

Quick answers

What does Caribou Biosciences do?
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011.
What is CRBU's market cap?
$43.62M, based on the Nov 5 close of $0.41.
Does Caribou Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CRBU is sold short?
12.6M shares, 13.5% of float, as of Oct 15, 2026.
What sector is CRBU in?
Healthcare, in the Biotechnology industry.

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

HQ: Berkeley, CA97 employeesListed Jul 23, 2021cariboubio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology